THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...

For patients with stage IA NSCLC, lung resections, including lobectomy and segmentectomy, are associated with improved long-term survival compared with wedge resection.

Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma InterestProvidence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean ...

Patients with extensive-stage small cell lung cancer (ES-SCLC ... to treat patients with resectable non–small cell lung cancer (NSCLC) as a neoadjuvant treatment with chemotherapy and continued ...

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “Acquired RUFY1-RET rearrangement as a ...

Among patients with stage IA non-small cell lung cancer, long-term survival was better with lobectomy or segmentectomy vs.

Researchers found that, in patients with stage III NSCLC, treatment with cCRT and an ICI was safe, but treatment with cCRT and 2 ICIs led to “excessive mortality.” ...

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...

Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events ...

Cullinan Therapeutics and its partner Taiho Pharmaceutical have reported a win for zipalertinib, with the primary endpoint of ...

A new case report details a novel genetic mutation linked to drug resistance in a non-small cell lung cancer patient ...